Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 2001 Jul;92(7):778–784. doi: 10.1111/j.1349-7006.2001.tb01161.x

Expression of Drug Resistance Genes in VP‐16 and mAMSA‐selected Human Carcinoma Cells

Yoshihito Matsumoto 1,2,✉, Hiroshi Takano 2, Katsuzo Kunishio 1, Seigo Nagao 1, Tito Fojo 2
PMCID: PMC5926780  PMID: 11473729

Abstract

The cell lines described in the present study were isolated as part of an effort to understand resistance to topoisomerase (topo) II inhibitors. To that end, 50 sublines were isolated from four human breast cancer cell lines, i.e., MCF‐7, T47D, MDA‐MB‐231, and ZR‐75B. As an initial step, a concentration that would be lethal to the majority of cells (IC99) was selected for both VP‐16 and mAMSA, for each cell line. The identification of an increasing number of putative drug resistance‐related proteins provided the opportunity to examine expression of the corresponding genes in the selected cell lines. Northern blot analysis revealed different responses to the selecting agents in the different cell lines. Previous studies examining expression of multidrug resistance (MDR)‐l in resistant cell lines had found undetectable levels in all cells. In the ZR‐75B sublines, increased expression of MDR‐associated protein (MRP) and canalicular multispecific organic anion transporter (cMOAT) was observed, and when the relative levels of overexpression were compared, a high correlation was found. In contrast, increased expression of MRP was observed in some of the MDA‐MB‐231 sublines, without a concomitant increase in cMOAT expression. Finally, in both T47D and MCF‐7 sublines, increased expression of cMOAT or MRP was observed infrequently, and where it occurred, was of a much smaller magnitude. In the analysis of expression of MRP, the highest levels were found in the ZR‐75B and MDA‐MB‐231 sublines, with lower levels in the MCF‐7 and T47D clones. Similarly, differences in the expression of topo IIα were observed among the sublines. Although the differences in expression appear to depend on the parental cell line from which the resistant sublines were derived, a strong correlation was observed between the expression of MRP and the levels of topo IIα. Cell lines with low levels of MRP had lower levels of topo IIα, while those with high levels of MRP maintained higher levels of topo IIα. While a reduced topo IIα level was common, there did not appear to be a compensating increase in the expression of topo IIβ or topo I or casein kinase (CK) IIα in any of the cell lines. While the possibility that such compensation could occur has been discussed and even reported in some cell lines, such an adaptation was not observed in the present study, suggesting that it is not common.

Keywords: Topoisomerase II, MRP, cMOAT, CK II, MDR‐1

Full Text

The Full Text of this article is available as a PDF (762.0 KB).

Reference

  • 1.Caron , P. R. , Watt , P. and Wang , J. C.The C‐terminal domain of Saccharomyces cerevisiae DNA topoisomerase II . Mol. Cell. Biol , 14 , 3197 – 3207 ( 1993. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Nelson , W. G. , Liu , L. F. and Coffey , D. S.Newly replicated DNA is associated with DNA topoisomerase II in cultured rat prostatic adenocarcinoma cells . Nature , 322 , 187 – 189 ( 1984. ). [DOI] [PubMed] [Google Scholar]
  • 3.Berger , J. C. , Gamblin , S. J. , Harrison , S. C. and Wang , J. C.Structure and mechnism of DNA topoisomerase II . Nature , 379 , 225 – 232 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 4.Ross , W. , Rowe , T. , Glisson , B. , Yalowich , J. and Liu , L. F.Role of topoisomerase II in modifying epipodophyllotoxin‐inducedDNA damage . Cancer Res. , 44 , 5857 – 5860 ( 1984. ). [PubMed] [Google Scholar]
  • 5.Vosberg , V. P.DNA topoisomerase: enzymes that control DNA conformation . Curr. Top. Microbiol. Immunol. , 114 , 19 – 102 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 6.Wang , J. C.DNA topoisomerase . Annu. Rev. Biochem. , 54 , 655 – 697 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 7.Maxwell , A. and Gellert , M.Mechanistic aspects of DNA topoisomerases . Adv. Protein Chem. , 38 , 69 – 109 ( 1986. ). [DOI] [PubMed] [Google Scholar]
  • 8.Nelson , E. M. , Tewey , K. M. and Liu , L. F.Mechanisms of antitumor drug action: poisoning ofmammalianDNA topoisomerase II on DNA by 4′‐(9‐acridinylamino)‐methanesulfon‐m‐anisidide . Proc. Natl. Acad.Sci. USA , 81 , 1361 – 1365 ( 1984. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Tewey , K. M. , Chen , G. L. , Nelson , E. M. and Liu , L. F.Intercalative antitumor drugs interfere with the breakage‐reunion reaction of mammalian DNA topoisomerase II . J. Biol Chem. , 259 , 9182 – 9187 ( 1984. ). [PubMed] [Google Scholar]
  • 10.Zwelling , L. A.DNA topoisomerase II as a target of antineoplastic drug therapy . Cancer Metastasis Rev. , 4 , 263 – 276 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 11.Austin , C. A. , Patel , S. and Fisher , L. M.Novel HeLa topoisomeraseIIis theIl‐b isoform: completecoding sequence and homology with other type II topoisomerases . Biochim. Biophys. Acta , 172 , 283 – 291 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 12.Chung , T. D. Y. , Drake , F. H. , Tan , K. B. , Per , S. R. , Crooke , S. T. and Mirabelli , C. K.Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes . Proc. Natl. Acad. Sci. USA , 86 , 9431 – 9435 ( 1989. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Drake , F. H. , Hofmann , G. A. , Bartus , H. F. , Mattern , M. R. , Crooke , S. T. and Mirabelli , C. K.Biochemical and pharmocological propertiesof p170 and p180 formsof topoisomerase II . Biochemistry , 28 , 8154 – 8160 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 14.Woessner , R.D. , Chung , T.D. Y. , Hofmann , G. A. , Mattern , M. R. , Mirabelli , C. K. , Drake , F. H. and Johnson , R. K.Differences between normal and ras‐transformed NIH‐3T3 cells on expression of the 170 kD and 180 kD forms of topoisomerase II . Cancer Res. , 50 , 2901 – 2908 ( 1990. ). [PubMed] [Google Scholar]
  • 15.Danks , M. K. , Warmouth , M. R. , Friche , E. , Granzen , B. , Bugg , B. Y. , Harker , W. G. , Zwelling , L. A. , Futscher , B. W. , Suttle , D. P. and Beck , W. T.Single‐strand conformational polymorphism analysis of the Mr 170,000 isozyme of DNA topoisomerase II in human tumor cells . Cancer Res. , 53 , 1373 – 1379 ( 1993. ). [PubMed] [Google Scholar]
  • 16.Cole , S. P. C. , Chanda , E. R. , Dicke , F. P. , Gerlach , J. H. and Mirski , S. E. L.Non P‐glycoprotein‐mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug induced DNA damage and reduced levels of topoisomerase II . Cancer Res. , 51 , 3345 – 3352 ( 1991. ). [PubMed] [Google Scholar]
  • 17.Cole , S. P. C. , Bhardwaj , G. , Gerlach , J. H. , Mackie , J. E. , Grant , C. E. , Almquist , K. C. , Stewart , A. J. , Kurz , E. U. , Duncan , A. M. V. and Deeley , R. G.Overexpression of a transporter gene in a multidrug resistant human lung cancer cell line . Science , 258 , 1650 – 1654 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 18.Grant , C. E. , Vadimarsson , G. , Hipfner , D. R. , Almquist , K. C. , Cole , S. P. C. and Deeley , R. G.Overexpression of multidrug resistance associated protein increases resistance to natural product drugs . Cancer Res. , 54 , 357 – 361 ( 1994. ). [PubMed] [Google Scholar]
  • 19.Lee , J. S. , Scala , S. , Matsumoto , Y. , Dickstein , B. , Robey , R. , Zhan , Z. , Altenberg , G. and Bates , S. E.Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P glycoprotein or MRP Overexpression . J. Cell. Biochem. , 65 , 513 – 526 ( 1997. ). [PubMed] [Google Scholar]
  • 20.Lorico , A. , Rappa , G. , Srimatkandada , S. , Catapano , C. V. , Fernandes , D.J. , Germino , J.F. and Sartorelli , A.C.Increased rate of VP‐16 efflux in a murine leukemia cell line overexpressing the multidrug resistance associated protein gene . Cancer Res. , 55 , 4352 – 4360 ( 1995. ). [PubMed] [Google Scholar]
  • 21.Paulusma , C. C. , Bosnia , P. J. , Zaman , G. J. , Bakker , C. T. , Otter , M. , Scheffer , G. L. , Scheper , R. J. and Borst , P.Congenital jaundice in rats with a mutation in a multidrug resistance associated protein gene . Science , 271 , 1126 – 1127 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 22.Taniguchi , K. , Wada , M. , Kohno , K. , Nakamura , T. , Kawabe , T. , Kawakami , M. , Kagotani , K. , Okumura , K. , Akiyama , S. and Kuwano , M.A human canalicular multi‐specific organic anion transporter gene is Overexpression in cisplatin resistant human cancer cell lines with decreased drug accumulation . Cancer Res. , 56 , 4124 – 4129 ( 1996. ). [PubMed] [Google Scholar]
  • 23.Beck , W. T. , Kim , R. and Chen , R. R.Novel actions of inhibitors of DNA topoisomerase U in drug‐resistant tumor cells . Cancer Chemother. Pharmacol. , 34 ( Suppl. ), S14 – S18 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 24.Lee , M. S. , Wang , J. C. and Beran , M.Two independent amsacrine resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II . J. Mol. Biol , 223 , 837 – 843 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 25.Matsumoto , Y.Morisaki , K. , Kunishio , K. , Nagao , S. , Takano , H. and Fojo , T.Incidence of mutation and deletion in topoisomerase II mRNA of etoposide and m‐AMSA resistant cell lines . Jpn. J. Cancer Chemother. , 25 , 1145 – 1149 ( 1998. ). [PubMed] [Google Scholar]
  • 26.Alghisi , G. C. , Roberts , E. , Cardenas , M. E. and Gasser , S. M.The regulation of DNA topoisomerase II by casein kinase II . Cell. Mol. Biol. Res. , 40 , 563 – 571 ( 1994. ). [PubMed] [Google Scholar]
  • 27.Cardenas , M. E. , Dang , Q. , Glover , C. V. C. and Gasser , S. M.Casein kinase II phosphorylates the eukaryote‐specific c‐terminal domain of topoisomerase II in vitro . EMBO J. , 11 , 1785 – 1796 ( 1992. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Crenshaw , D. W. and Hsieh , T. S.Function of the hydrophilic carboxyl terminus of type II DNA topoisomerase from Drosophilamelanogaster . J. Biol. Chem. , 268 , 21335 – 21343 ( 1993. ). [PubMed] [Google Scholar]
  • 29.Wasserman , R. A. , Austin , C. A. , Fisher , L. M. and Wang , J. C.Use of yeast in the study of anticancer drugs targeting DNA topoisomerases: expression of a functional recombinant human DNA topoisomerase II alpha in yeast . Cancer Res. , 53 , 3591 – 3596 ( 1993. ). [PubMed] [Google Scholar]
  • 30.Wells , N. J. , Addison , C. M. , Fry , A. M. , Ganapathi , R. and Hickson , I. D.Serine 1524 is a major site of phosphorylation on human topoisomerase Ha protein in vivo and is a substrate for casein kinase II in vitro . J. Biol. Chem. , 270 , 29746 – 29751 ( 1994. ). [PubMed] [Google Scholar]
  • 31.Wells , N.J. , Fry , A.M. , Guano , F. , Norbury , C. and Hickson , I. D.Cell cycle phase‐specific phosphorylation of human topoisomerase Hoc . J. Biol.Chem. , 269 , 28357 – 28363 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 32.Skehan , P. , Storeng , R. , Scudiero , D. , Monks , A. , McMahon , J. , Vistica , D. , Warren , J.T. , Bokesch , H. , Kenney , S. and Boyd , M. R.New colorimetric cytotoxicity assay for anticancer‐drug screening . J. Natl. Cancer Inst. , 82 , 1107 – 1112 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 33.Matsumoto , Y. , Takano , H. and Fojo , T.Cellular adaptation to drug exposure: evolution of the drug‐resistant phenotype . Cancer Res. , 57 , 5086 – 5092 ( 1997. ). [PubMed] [Google Scholar]
  • 34.Woessner , R. D. , Mattern , M. R. , Mirabelli , C. K. , Johnson , R. K. and Drake , F. H.Proliferation‐ and cell cycle‐dependent differnces in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH‐3T3cells . Cell Growth Differ. , 2 , 209 – 214 ( 1991. ). [PubMed] [Google Scholar]
  • 35.Harker , W. G. , Slade , D. L. , Parr , R. L. , Feldhoff , P. W. , Sullivan , D. M. and Holguin , M. H.Alterations in the topoisomerase IIa gene, messenger RNA, and subcellular protein distribution as well reduced expression of the DNA topoisomerase IIβ enzyme in mitoxantrone‐resistant HL‐60 human leukemiacell line . Leukemia , 20 , 1707 – 1716 ( 1996. ). [PubMed] [Google Scholar]
  • 36.Cole , S. P. C. , Sparks , K. E. , Fraser , K. , Loe , D. W. , Grant , C. E. and Wilson , G. M.Pharmacological characterization of multidrug resistant MRP transfected human tumor cells . Cancer Res. , 54 , 5902 – 5910 ( 1994. ). [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES